A primer probe combination and kit for detecting liver cancer gene methylation
Through the specific methylation detection technology of liver cancer based on digital PCR, the diagnosis of liver cancer is solved by using specific gene methylation markers, and the problem of insufficient diagnostic sensitivity and specificity in the existing technology is solved, achieving efficient and accurate liver cancer screening and diagnosis.
Patent Information
- Application Number
- CN202411170023.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-08-26
AI Technical Summary
The existing diagnostic methods for liver cancer are insufficient in sensitivity and specificity, making it difficult to accurately identify benign and malignant lesions of liver space-occupying diseases, especially lacking effective strategies in early detection.
Develop a specific methylation detection technology for liver cancer based on digital PCR, using methylation markers of ACP1, BMPR1A, PLAC8 and RNF135 genes for gene methylation detection, and by designing specific primer probe combinations and kits, it can achieve Automatic detection of peripheral blood samples.
It improves the certainty and feasibility of liver cancer diagnosis, provides a detection method with high analytical sensitivity, suitable for large sample examinations, with objective and repetitive results, and does not rely on professional doctors, and is suitable for screening for high-risk patients.
Smart Images

Figure CN118685520B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of liver cancer detection, and in particular to a primer probe combination and a kit for liver cancer gene methylation detection. Background Art
[0002] Hepatocellular carcinoma (PLC) is the sixth most commonly diagnosed cancer. For some liver space-occupying diseases with atypical imaging and biomarker changes, it is often difficult to accurately distinguish benign from malignant lesions. Accurate diagnosis of PLC type is important for selecting appropriate treatment methods and formulating follow-up plans. Currently, the diagnosis of HCC mainly relies on serum alpha-fetoprotein (AFP) levels and imaging, which has limitations. The Asia-Pacific Association for the Study of the Liver (APASL) HCC Guidelines no longer recommend AFP levels as a screening tool for monitoring HCC because it lacks sufficient sensitivity and specificity. Early detection is the only hope for effective treatment of HCC patients, which emphasizes the role of key screening strategies in monitoring high-risk patients. Therefore, strategies are urgently needed to improve the certainty and feasibility of diagnosis.
[0003] DNA methylation of the promoter CpG island (CGI) of tumor suppressor gene (TSG) is an important mechanism that often induces the occurrence and development of various cancers. Abnormal methylation of TSGs promoter CpG sites can change the spatial structure of chromatin, leading to low or no expression of tumor suppressor genes. Studies have shown that abnormal gene methylation is closely related to the occurrence of HCC and ICC, and has a potential role in screening diagnostic biomarkers and therapeutic targets. When hypermethylation of tumor suppressor genes occurs in the promoter region of the gene, the gene may be silenced and inactivated, losing its tumor suppressor function and cancer occurs. Summary of the invention
[0004] The purpose of the present invention is to provide a liver cancer-specific methylation detection technology developed based on digital PCR for the screening and diagnosis of liver cancer.
[0005] The present invention provides a primer-probe combination for detecting methylation of liver cancer genes, comprising a biomarker composed of the ACP1 gene, the BMPR1A gene, the PLAC8 gene and the RNF135 gene as a primer sequence corresponding to the methylation marker, wherein the methylation marker is composed of a methylated nucleotide sequence in a target region of the ACP1 gene, the BMPR1A gene, the PLAC8 gene and the RNF135 gene;
[0006] The primer sequences are specifically shown as follows:
[0007] The forward primer nucleic acid sequence of the ACP1 gene is: GGTCGCGTTTAGGTTTTC;
[0008] The nucleic acid sequence of the rear primer of ACP1 gene was: GCGAAACTCTAAACTTTTCG;
[0009] The forward primer nucleic acid sequence of the BMPR1A gene was: TGTTTCGTTTCGTTTCGGATACG;
[0010] The nucleic acid sequence of the rear primer of the BMPR1A gene was: TTACCGACGACTAACCCTCCT;
[0011] The nucleic acid sequence of the forward primer of the PLAC8 gene is: GTTCGTTGTTCGGTTTAC;
[0012] The nucleic acid sequence of the rear primer of the PLAC8 gene is: ACGTCTACGAATAACTACC;
[0013] The forward primer nucleic acid sequence of the RNF135 gene is: CGGTTTAATTTCGACGTTCGC;
[0014] The nucleic acid sequence of the rear primer of the RNF135 gene is: CAACCACACGAAAACGACGA.
[0015] Optionally, a probe is also designed for the primer, and the probe sequence is specifically represented as follows:
[0016] The probe nucleic acid sequence of the ACP1 gene is: AAACGAAACGATTCCGAAATCCCTAAA;
[0017] The probe nucleic acid sequence of the BMPR1A gene is: CCGACAACTAAACGCCGAACTCCGC;
[0018] The probe nucleic acid sequence of the PLAC8 gene is: AACCATTCGCCGAAACGACG;
[0019] The probe nucleic acid sequence of the RNF135 gene is: CCAAACCCAAACCCGCCATAACCAACA.
[0020] Optionally, a set of primer sequences corresponding to a reference marker GAPDH gene is also included, which are specifically represented as follows:
[0021] The forward primer nucleic acid sequence of the GAPDH gene is: GAGGTTAAATATAGTTGTTGA;
[0022] The nucleic acid sequence of the rear primer of the GAPDH gene is: CCCAAAACTTTAATTTACCA.
[0023] Optionally, a probe is also designed for the primers corresponding to the reference marker GAPDH gene, and the probe sequence is specifically represented as follows:
[0024] The probe nucleic acid sequence of the GAPDH gene is: ACCTATCCTTCCTAACTCT.
[0025] The present invention also provides a kit for detecting liver cancer gene methylation, wherein the kit comprises the above-mentioned primer-probe combination for detecting liver cancer gene methylation.
[0026] Optionally, the primer probe combination for liver cancer gene methylation detection consists of ACP1 gene, BMPR1A gene, PLAC8 gene and RNF135 gene.
[0027] Compared with the prior art, the present invention has the following beneficial effects:
[0028] The present invention screens and diagnoses liver cancer by automatically detecting gene methylation rates from peripheral blood; it has the following specific advantages: ① peripheral blood samples are taken for non-invasive and automated testing, which does not rely on professional doctors, has high repeatability and objective results; ② the gene methylation markers that are highly correlated with liver cancer are screened, and digital PCR detection with high analytical sensitivity is used for detection, which has better clinical accuracy; ③ high-throughput detection, suitable for large sample inspection.
[0029] In addition to the above-described purposes, features and advantages, the present invention has other purposes, features and advantages. The present invention will be further described in detail with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] The drawings constituting a part of this application are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. In the drawings:
[0031] FIG1 (a) is a box plot of the methylation rate of the ACP1 gene in liver cancer and benign lesions in the experimental examples of the present invention (where P=0.0001);
[0032] FIG1( b ) is a box plot of the methylation rate of the BMPR1A gene in liver cancer and benign lesions in the experimental examples of the present invention (where P < 0.0001);
[0033] FIG1( c ) is a box plot of the methylation rate of the PLAC8 gene in liver cancer and benign lesions in the experimental examples of the present invention (where P = 0.0001);
[0034] FIG1( d ) is a box plot of the methylation rate of the RNF135 gene in liver cancer and benign lesions in the experimental example of the present invention (where P = 0.0011);
[0035] FIG2 (a) is a schematic diagram of the curve of the methylation rate of the ACP1 gene in subjects with liver cancer and benign lesions in the experimental example of the present invention;
[0036] FIG2 (b) is a schematic diagram of the curve of BMPR1A gene methylation rate in subjects with liver cancer and benign lesions in the experimental example of the present invention;
[0037] FIG2 (c) is a schematic diagram of the curve of the methylation rate of the PLAC8 gene in subjects with liver cancer and benign lesions in the experimental example of the present invention;
[0038] FIG2( d ) is a schematic diagram of the curve of the methylation rate of the RNF135 gene in subjects with liver cancer and benign lesions in the experimental example of the present invention. DETAILED DESCRIPTION
[0039] The following are specific embodiments of the present invention and the accompanying drawings to further describe the technical solution of the present invention, but the present invention is not limited to these embodiments.
[0040] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art of the present invention. The terms used in the present invention specification herein are only for the purpose of describing specific embodiments and are not intended to limit the present invention. Embodiment 1:
[0041] (I) Screening out gene methylation markers for detecting liver cancer;
[0042] Step 1. Through bioinformatics analysis, the gene methylation markers ACP1 gene, BMPR1A gene, PLAC8 gene and RNF135 gene for liver cancer detection were screened out, and the chromosomal regions of the above genes were selected as chr2: 263400-264438, chr10: 88515426-88516517, chr4: 84030630-84031309 and chr17: 29298046-29298606, respectively.
[0043] Table 1 Screened gene methylation markers and chromosomal regions for liver cancer detection
[0044]
[0045] Step 2: Select any one of the GAPDH gene, βactin gene or COL2A1 gene as the internal reference gene (IC). Design primers and probes for the PCR detection reaction based on the nucleotide sequences (B-DNA) after bisulfite conversion of the target region chr2 of the ACP1 gene: 263400-264438, the target region chr10 of the BMPR1A gene: 88515426-88516517, the target region chr4 of the PLAC8 gene: 84030630-84031309, and the target region chr17 of the RNF135 gene: 29298046-29298606.
[0046] Table 2 Sequences and melting temperatures (Tm) of primer probes
[0047]
[0048] In Table 2, the fluorescent group of the probe is set to any one of FAM, HEX, Cy5, Cy5.5, ROX or ATTO 590; the quenching group is set to any one of BHQ1, BHQ1 or BHQ3. Different fluorescent groups can be selected for detection in the same PCR reaction system.
[0049] Furthermore, the ACP1 gene, also known as the LMWPTP gene, is a low molecular weight protein tyrosine phosphatase that is involved in the drug resistance and migration of tumor cells. There is a positive correlation between the amount of this enzyme in cancer and poor prognosis.
[0050] Specifically, the chr2:263400-264438 sequence of the ACP1 gene was searched in the UCSC gene database, and the nucleotide sequence of the positive strand was selected from: >hg19_dna range=chr2:263400-264438 5'pad=0 3'pad=0 strand=+repeatMasking=none, and its original sequence is as follows:
[0051]
[0052] After bisulfite conversion, the C in the CG site remains unchanged, and other Cs are converted to Ts, resulting in the bisulfite-converted nucleotide sequence (B-DNA) as follows:
[0053] GCGTTAAGGTTTAGCGATTAGAGAGGATTCGTGTTCGTCGCGATTTCGCGTTCGTTTTGTGGTTTCGCGATTTCGGCGTTAGGTGTTGGGGGGATCGGTTTTTTTTTTTCGGGTGTGAGGGGTTGGTTTTTTTTTTTTAGGTTGGGGGGTTGGTAAATTCGAATTTCGTCGGCGTTTTAGTTAAGGTTTTTTTTTCGCGTTTGTCGCGGGTTTTACGTATATTTTAAGCGCGCGTATTCGATTTAAATTTTAGAGACGTTTTTGTGGAACGGAAGGATGGTCGTTGATATTTCGTCGTTTAAATATTAGGAAGTTAAAAATAATACGATTATCGTTATTATTTTAAATTTCGGAATAGTTTTTTTAAAAATGGAAAAGACGGTGGTTAAATTTTAATTAAAATCGTTGTGGTTAAGAAAGTTTTGGAAGTTGTTTTATTTTAATTTTGGGCGGTTTGCGGTTAATAGACGCGCGATTTAGAAATTTTAGAGGTATCGTCGGTTTTTTCGTTTTTTTTTTTTTATTATCGTTTAGTTTTTGAGAGGGGAGGGTGTTGTCGGATAGGTGGGTTTTCGGGTATTTATTGTTGTTCGTTCGGTCGCGGCGTTTCGTTTCGAGGTTGTTTAGGAAGAGGAAGGCGCGTTGTTTCGTTTCGCGGATAAGGAGGTTTTAGCGAGGGCGTATTTGCGGTAGGTGACGAAGGAGGCGGCGTAAAATATTCGTCGTGTACGTTTCGCGGGATAAAAATTACGCGTTCGTCG G GT CGCG TTTAGGTTTT C G TT TTTAGGGATTTCGGAAT CG TTT CG TTT TTAAGAT CG AAAAGTTTTAGAGTTT CGC GGCGGTTTTAAGTACGGTGTTGGGGGTGGGGGTTTTAGGGAGCGTTTAGGTTTAAGGTCGTTTTGGTTCGGCGTGGATTTCGCGGGGTTTAAGGTAGGTTTTCCGTGATTCGTTTAGTTTTTTTATGCGAATTCGAACGATAGGTATTATAGTTCGTTACGTGCGCGAGATTCGCGTTGTGTTTTAATTTAGGTGGGCGGT
[0054] In the above nucleotide sequence, the underlined part is the position of the primer probe, and the tilted CG is the methylation site to be detected.
[0055] Further, bone morphogenetic protein (BMP) receptors are a family of transmembrane serine / threonine kinases, which include type I receptors BMPR1A and BMPR1B and type II receptor BMPR2. Bone morphogenetic proteins (BMP) and BMP receptors are widely involved in osteolytic metastasis of cancer. The chr10:88515426-88516517 sequence of the BMPR1A gene was searched in the UCSC gene database, and the nucleotide sequence of the negative strand was selected from: >hg19_dna range=chr10:88515426-88516517 5'pad=0 3'pad=0strand=- repeatMasking=none, and its original sequence is as follows:
[0056]
[0057] After bisulfite conversion, the C in the CG site remains unchanged, and the other Cs are converted to Ts. The nucleotide sequence after bisulfite conversion (B-DNA) is as follows:
[0058] GGACGGACGCGTCGAGTTTAAGTTTTTGTTCGTTTTTGGTTTTTTTTTTTTCGTTTGTTTTTTTTTTTTTTTCGTTAAGTTCGGTAGGCGGATTTTAATTTTTGTAGCGGTCGTCGTTATCGTCGT CGATTTTTGTTAGGAGGGGAGGGCGGCGCGGGTGCGGGGGTTTGGGGGAGGGGCGGGGCGTTCGCGGGTTTTGTACGGCGCGCGCGTATTGGGAAGGTTTTCGTTCGCGTCGCGCGTATTCGATTACGGGCGTT TGTTT CG TTT CG TTT CG STREET CG AAAAGAGTCGAGCGTACGGCGGAAGCGTTCGAAGAGTTC G CG GAGTT CG G CG TTTAGTTGT CG G GG AGGAGGTTAGTCGT CG GT AA GGGGGCGTCGAGTTGTTGGTGCGGGCGGGAGTCGGGGTTGTTTTTTCGCGCGGGTTCGTCGGTTTTTTTTTATAAGTTAGTTTTATAGTTGTCGTTCGGGTAGTTTTTCGTAGACGTCGTAGGTAGTACGCGATGGAACGCGGCGGAGGGGAGCGTGGATACGGTTGTCGGGCGTTGCGGTTATCGGCGTTTTGGACGTTCGTTTCGGTTTTCGGGGTCGGATATTTTTATTTTCGCGGGTTTTTTCGCGTGGATTTTTTTTTCGGTCGATATTTATATTGCGGTGAACGTTAGTTAGTTGGCGTGAAATAAGGTCGTTGGGAAGGTATTAAGTTATTAAGGTGGGGGATGGTTAGGTCGTGGTAGTTGCGATAAAGAAAAATATAAGTTATATTGTATTTGTTTTTCGTTTATTTATCGTTTTCGGCGTTTTTTTTCGGGTTTTTTGTTAGCGTGTCGAGGCGTAGGTAGGGTGATGGAGGTTTTTCGGTCGGGAGGATTTGTCGGGGAGAGCGGTTTTTTTTATCGATTCGGGAGCGTTAGGTTCGGCGCGTTCGGGTTTTTGTGATTTGCGAGTTCGCGAATTTTAGCGGTATAAGATAAGGAGCGGCGAGGGTTTAATAGGATTGAGGTTAGTTAGTTATAAATACGTTTTTAGTTTTATCGCGGGTTTACGTTGGTGATTTCGTGTATTTTTCGGAGGTTTATTTCGT
[0059] In the above nucleotide sequence, the underlined part is the position of the primer-probe, and the slanted CG is the methylation site to be detected.
[0060] Furthermore, PLAC8 gene mutation and biological information transmission play an important role in tumor process, and its overexpression promotes cancer cell growth through Wnt / β-Catenin signaling. The chr4:84030630-84031309 sequence of PLAC8 gene was searched in UCSC gene database, and the nucleotide sequence of negative strand was selected from: >hg19_dna range=chr4:84030630-84031309 5'pad=0 3'pad=0 strand=- repeatMasking=none, and its original sequence is as follows:
[0061] CGGTGAGCCTGGGCGCCCGGAGCGACAGAGCGGCGGGTGCCCGGGAGGAAGCGGCGCCAGCCCTGCCCAGCTTTGCGGCTCCTGGCGCCTGCCGCTGGGGCTGGGCTCCGAGACCGCGCGCCCGCTGCCCGGTTCACGCCGAGTCCCCAGCGGCGCGCCGCCCCGGCGAA TGGTCCCCCGAGGGCAGCCATCCGCAGACGCAGTTCCCTGATTGCCCCAGCAAAAATGGGCGGTCTCCTTGGGATAGATTCTGCGCGGGCTGCTCTTAAGAATTTACCGGCAGGCAGGTCTGGTCCCAGCAGAGGAGACCCAGGGGTCCCAGAGCTGGGCTGGCGGGAGG CGTAATCCGGCGGGGTGAGGGTTGATCGAAGAGCCCCGCGCGCAGCTGCCGCTCACAGCCCCTTCCCGAGTGCAGAGCGGGCAGAGAAGGTAAGAAGCCCACCCACCCACTCCCCGCCTCCTGAAGCCCGTGCTTCAGACCTGTCCCTGCAACTGGGGAAGAGCCAGGCG GGCTCTCCGCCTCCTCGATCCTCCTCCCTGGAAGAGGCCCGAAGGCAGCGGCCGCCAGACACACGTTCGCCTAGTCCGTCACCCGACGGCTCTGCCCCTCAACAGGGGCTCCTCACCGCCACGTACACATCCGCGGCTCATGCACGCCCTGAATGATCGGCTCAGCCGG
[0062] After bisulfite conversion, the C in the CG site remains unchanged, and the other Cs are converted to Ts. The nucleotide sequence after bisulfite conversion (B-DNA) is as follows:
[0063] CGGTGAGTTTGGGCGTTCGGAGCGATAGAGCGGCGGGTGTTCGGGAGGAAGCGGCGTTAGTTTTGTTTAGTTTTGCGGTTTTTGGCGTTTGTCGTTGGGGTTGGGTTTCGAGATCGCGC GTT CG TTGTTT CG GTTTTA C G TCGAGTTTTTAGCGGCG <h2 style=";text-align:left;direction:ltr"> CG <h2 style=";text-align:left;direction:ltr"> TCGTTT<h2 style=";text-align:left;direction:ltr"> CG <h2 style=";text-align:left;direction:ltr"> G<h2 style=";text-align:left;direction:ltr"> CGA <h2 style=";text-align:left;direction:ltr"> ATGGTT TTTCGAG GGTAGTTATT CG TAGA CG T AGTTTTTGATTGTTTTAGTAAAAATGGGCGGTTTTTTTGGGATAGATTTTGCGCGGGTTGTTTTTAAGAATTTATCGGTAGGTAGGTTTGGTTTTAGTAGAGGAGATTTAGGGGTTTT AGAGTTGGGTTGGCGGGAGGCGTAATTCGGCGGGGTGAGGGTTGATCGAAGAGTTTCGCCGTAGTTGTCGTTTATAGTTTTTTTTCGAGTGTAGAGCGGGTAGAGAAGGTAAGAAGTTT ATTTATTTATTTTTCGTTTTTTGAAGTTCGTGTTTTAGATTTGTTTTTGTAATTGGGGAAGAGTTAGGCGGGTTTTTCGTTTTTTCGATTTTTTTTTGGAAGAGGTTCGAAGGTAGCG GTCGTTAGATATACGTTCGTTTAGTTCGTTATTCGACGGTTTTGTTTTTTAATAGGGGTTTTTTTATCGTTACGTATATATTCGCGGTTTATGTACGTTTTGAATGATCGGTTTAGTCGG
[0064] In the above nucleotide sequence, the underlined part is the position of the primer probe, and the tilted CG is the methylation site to be detected.
[0065] Furthermore, the expression of RING finger protein 135 (RNF135) was strongly correlated with immune cell infiltration, tumor mutation load, microsatellite instability, and immune regulatory factors. RNF135 may promote the proliferation, migration, and invasion of triple-negative breast cancer cells. RNF135 may be used as a biomarker to predict tumor behavior. The chr17:29298046-29298606 sequence of the RNF135 gene was searched in the UCSC gene database, and the nucleotide sequence of the positive strand was selected from: >hg19_dna range=chr17:29298046-29298606 5'pad=0 3'pad=0 strand=+ repeatMasking=none, and its original sequence is as follows:
[0066] TCGCCCGGCTCAACCCCGACGTCCGCGCCCCGGCCGCCTGTTGGCCATGGCGGGCCTGGGCCTGGGCTCCGCCGTTCCCGTGTGGCTGGCCGAGGACGACCTCGGCTGCATCATCTGCCAGGGGCTGCTGGACTGGCCCG CCACGCTGCCCTGCGGCCACAGCTTCTGCCGCCACTGCCTGGAGGCCCTGTGGGGCGCCCGCGACGCCCGCCGCTGGGCCTGCCCCACTTGCCGCCAGGGCCGCGCAGCAGCCGCACCTGCGGAAGAACACGCTACTG CAGGACCTGGCCGACAAGTACCGCCGCGCCGCACCGAGATACAGGCGGGCTCCGACCCTGCCCACTGCCCCTGCCCGGGTCCAGTTCCCTCTCCAGCGCGGCCGCGAGGCCCCGGCGCCGCCCGGAACTGCAGCGGGT AGGGAGGCCGGGCCCGCAGCTCCCCTGGCTCCCCCGGGCTGCCCGCCGCCTGACCCTTTCCCATGTGGCTCGAACCCCTTTCCTCAGCCGTTCTACTTTTACGTTTCCTTTTCTCAGTCTAAAAGTCGAGTTCCGCTCTTCG
[0067] After bisulfite conversion, the C in the CG site remains unchanged, and the other Cs are converted to Ts. The nucleotide sequence after bisulfite conversion (B-DNA) is as follows:
[0068] TCGTT CG GTTTAATTT CG ACGTT CGC GTTTCGGTCGTT TGTTGGTTATGG CG GGTTTGGGTTTGG GTT T CG T CG TTTT CG TGTGGTTG GTCGAGGACGATTTCGGTTGTATTATTTGTTAGGGGTTGTTGGATTGGTTCGTTACGTTGTTTTGCGGTTATAGTTTTTGTCGTTATTGTTTGGAGGTTTTGTGGGGCGTTCGCGACGTTCGTCGTTGGGTTTGTTTTATTTGTCGTTAGGGCGTCGCGTAGTAGTCGTATTTGCGGAAGAATACGTTATTGTAGGATTTGGTCGATAAGTATCGTCGCGTCGTACGCGAGATATA GGCGGGTTTCGATTTTGTTTATTGTTTTTGTTCGGGTTTTAGTTTTTTTTAGCGCGGTCGCGAGGTTTCGGCGTCGTTCGGAATTGTAGCGGGTAGGGAGGTCGGGTTCGTAGTTTTTTTGGTTTTCGGGTTGTTCGTCGTTTGATTTTTTTTTATGTGGTTCGAATTTTTTTTTTGTCGTTTTATTTTTACGTTTTTTTTTTTAGTTTAAAAGTCGAGTTTCGTTTTTCG
[0069] In the above nucleotide sequence, the underlined part is the position of the primer probe, and the tilted CG is the methylation site to be detected.
[0070] Step 3: Based on the digital PCR platform, the emulsion PCR PCR reaction system in nucleic acid aptamer screening as shown in Table 3 and the PCR reaction program as shown in Table 4 are constructed to amplify the target gene. Among them, the emulsion PCR in nucleic acid aptamer screening is a PCR amplification system using microdroplets in an oil-in-water emulsion system as a reactor. That is, the PCR reaction system constructed in this application is a PCR reaction system of an oil-in-water single molecule template.
[0071] Table 3 PCR reaction system of oil-in-water single-molecule template
[0072]
[0073] Since MIX contains DNA polymerase, Mg ions, dNTPs, etc. for PCR amplification reaction, the amount of primer probe added can be appropriately adjusted according to the number of genes to be detected in the reaction system.
[0074] Table 4 Reaction scheme
[0075]
[0076] Step 4: Interpretation of gene methylation levels;
[0077] The calculation formula of gene methylation rate is set as: gene methylation rate Mp = gene methylation copy number / reference gene copy number. Embodiment 2:
[0078] The present invention also provides a method for detecting liver cancer using the liver cancer gene methylation markers described above, which specifically includes the following process:
[0079] 1. Sample preparation;
[0080] Genomic DNA was extracted from stored plasma or serum samples. After DNA extraction, sulfite conversion was performed using a methylation conversion kit (Methylation Detection Sample Pretreatment Kit, Hunan Hongya Gene Technology Co., Ltd., Changsha, China). The manufacturer's instructions were followed to convert methylated cytosine (C) to uracil (U) and to be recognized as thymine (T) in the PCR amplification reaction.
[0081] 2. Preparation of reaction system;
[0082] The methylation rates of genes ACP1, BMPR1A, PLAC8, and RNF135 were detected on a digital PCR instrument. Since different fluorescent groups can be labeled on the probes for methylation detection of each gene, a reaction system can be prepared for multiple genes. However, it is worth noting that each reaction system must detect the internal reference gene (IC). According to the requirements of the digital PCR instrument, a reaction system containing buffer, primers, probes, dNTPs, DNA polymerase, etc. was prepared.
[0083] 3. Partitioning or droplet generation;
[0084] The reaction system is distributed into a large number of tiny partitions or droplets through microfluidics, oil-in-water emulsification or other methods. Theoretically, there is only one target gene template in one partition or droplet, achieving one copy per well.
[0085] 4. Capping and thermal cycling;
[0086] The partitions or droplets are capped with a capping device that comes with the instrument to prevent liquid evaporation and contamination during the thermal cycle. Then, the thermal cycle of PCR amplification is performed to amplify the nucleic acid converted from the target gene in each partition or droplet. During the thermal cycle, the target gene methylation probe is used to detect the amplification of the target gene. Different target genes are distinguished by the fluorescent color.
[0087] 5. Interpretation of results;
[0088] 1. The calculation of gene methylation rate is as follows:
[0089] Digital PCR directly calculates the number of DNA molecules in each PCR reaction. The gene methylation (Gene_M) probe counts the number of methylated copies, the internal reference gene (IC) probe counts the total number of copies, and the gene methylation rate The counting formula is:
[0090] ;
[0091] 2. Interpretation of the results of gene methylation marker diagnosis of liver cancer, see Table 5 for details.
[0092] Table 5 Interpretation of gene methylation detection in liver cancer
[0093]
[0094] Experimental example:
[0095] 70 cases with known pathological results were collected, including 26 benign lesions and 44 liver cancer cases. Among the liver cancer cases, there were 20 cases of hepatocellular carcinoma HCC, 15 cases of cholangiocarcinoma ICC, and 5 cases of small cell neuroendocrine carcinoma SCNC. ACP1, BMPR1A, PLAC8, and RNF135 were detected according to Example 1. There were statistically significant differences in the methylation rates of ACP1, BMPR1A, PLAC8, and RNF135 genes in liver cancer and benign lesions, as shown in Figures 1 (a) to 1 (d). The areas under the ROC curves of ACP1, BMPR1A, PLAC8, and RNF135 gene methylation for the diagnosis of liver cancer were 0.789 (P < 0.001), 0.913 (P < 0.001), 0.784 (P < 0.001), and 0.734 (P = 0.001), respectively, all of which had good diagnostic capabilities. As shown in Figures 2(a) to 2(d), the critical value is taken according to the maximum Youden index principle. In this embodiment, the critical value of ACP1 gene methylation is 0.045, and the sensitivity and specificity are 79.5% and 88.5%, respectively; the critical value of BMPR1A gene methylation is 0.059, and the sensitivity and specificity are 90.9% and 92.3%, respectively; the critical value of PLAC8 gene methylation is 0.058, and the sensitivity and specificity are 88.6% and 84.6%, respectively; the critical value of RNF135 gene methylation is 0.047, and the sensitivity and specificity are 79.5% and 84.6%, respectively.
[0096] Table 6 Sensitivity and specificity of single gene methylation in diagnosing liver cancer
[0097]
[0098] Select two genes for joint testing. If any one gene is positive, the joint test result is judged as positive, otherwise it is judged as negative. The sensitivity of double-gene joint testing for diagnosing liver cancer is higher than that of the corresponding single gene. The clinical sensitivity and specificity are shown in the table below.
[0099] Table 7 Sensitivity and specificity of combined double gene methylation in the diagnosis of liver cancer
[0100]
[0101] Select three or four genes for combined testing. If any one gene is positive, the combined test result is considered positive. Otherwise, it is considered negative. For the diagnostic clinical sensitivity and specificity of three or four gene combined testing, please see the table below.
[0102] Table 8 Sensitivity and specificity of multi-gene methylation combined diagnosis of liver cancer
[0103]
[0104] In the application of liver cancer detection, multiple genes are combined to form complementarity and reduce the missed diagnosis of liver cancer. See the table below. This plays an important role in the prevention and treatment of liver cancer.
[0105] Table 9 Gene methylation rates and interpretation results in peripheral blood of patients with liver cancer
[0106]
[0107]
[0108] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.
Claims
1. A primer-probe combination for detecting methylation of liver cancer genes, characterized in that: The method comprises a primer-probe combination for detecting a biomarker composed of the ACP1 gene, the BMPR1A gene, the PLAC8 gene and the RNF135 gene as a methylation marker, wherein the methylation marker is composed of a nucleotide sequence methylated in a target region of the ACP1 gene, the BMPR1A gene, the PLAC8 gene and the RNF135 gene; The primers are specifically shown as follows: The forward primer nucleic acid sequence of the ACP1 gene is: GGTCGCGTTTAGGTTTTC; The nucleic acid sequence of the rear primer of ACP1 gene was: GCGAAACTCTAAACTTTTCG; The forward primer nucleic acid sequence of the BMPR1A gene was: TGTTTCGTTTCGTTTCGGATACG; The nucleic acid sequence of the rear primer of the BMPR1A gene was: TTACCGACGACTAACCCTCCT; The nucleic acid sequence of the forward primer of the PLAC8 gene is: GTTCGTTGTTCGGTTTAC; The nucleic acid sequence of the rear primer of the PLAC8 gene is: ACGTCTACGAATAACTACC; The forward primer nucleic acid sequence of the RNF135 gene is: CGGTTTAATTTCGACGTTCGC; The nucleic acid sequence of the rear primer of the RNF135 gene is: CAACCACACGAAAACGACGA; The probe is specifically represented as follows: The probe nucleic acid sequence of the ACP1 gene is: AAACGAAACGATTCCGAAATCCCTAAA; The probe nucleic acid sequence of the BMPR1A gene is: CCGACAACTAAACGCCGAACTCCGC; The probe nucleic acid sequence of the PLAC8 gene is: AACCATTCGCCGAAACGACG; The probe nucleic acid sequence of the RNF135 gene is: CCAAACCCAAACCCGCCATAACCAACA.
2. The primer-probe combination for detecting methylation of liver cancer genes according to claim 1, characterized in that: It also includes a set of primer probes corresponding to a reference marker GAPDH gene, which are specifically shown as follows: The forward primer nucleic acid sequence of the GAPDH gene is: GAGGTTAAATATAGTTGTTGA; The nucleic acid sequence of the rear primer of the GAPDH gene is: CCCAAAACTTTAATTTACCA; The probe nucleic acid sequence of the GAPDH gene is: ACCTATCCTTCCTAACTCT.
3. A kit for detecting methylation of liver cancer genes, characterized in that: The kit comprises the primer-probe combination for detecting liver cancer gene methylation according to claim 1.
Citation Information
Patent Citations
Kit for detecting metastatic hepatoma cells in blood, marker and method thereof
CN102206708A
Gene methylation panel for diagnosing and predicting curative effect and prognosis of liver cancer
CN106947830A
Detecting hepatocellular carcinoma
CN109790198A
Gene methylation digital PCR kit for early screening of liver cancer and application thereof
CN112410425A
Application of liver cancer marker in preparation of liver cancer detection product and detection kit
CN114164275A
